Clinical trials: Haematologic Neoplasms
Haematologic Neoplasms
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in…
- Trial name
- NCT07064122
- Testing
- AZD2962
- Where
- 21 sites in United States, Australia and 5 more
- Volunteers
- 72 people
- Sponsor
- AstraZeneca
Neoplasms, Haematologic
Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients
Afuresertib, an AKT inhibitor, has shown in vitro and in vivo activity in multiple myeloma models. AKT inhibitor has also demonstrated encouraging clinical activity in multiple myeloma.
- Trial name
- NCT02177682
- Testing
- Afuresertib
- Where
- 5 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals